| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Itaru Miura, Tetsuya Shiga, Akihiko Katsumi, Keiko Kanno-Nozaki, Hirobumi Mashiko, Shin-Ichi Niwa, Hirooki Yab. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. Human psychopharmacology. vol 29. issue 2. 2014-11-21. PMID:24590545. |
switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. |
2014-11-21 |
2023-08-12 |
Not clear |
| Itaru Miura, Tetsuya Shiga, Akihiko Katsumi, Keiko Kanno-Nozaki, Hirobumi Mashiko, Shin-Ichi Niwa, Hirooki Yab. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. Human psychopharmacology. vol 29. issue 2. 2014-11-21. PMID:24590545. |
we investigated the effects of aripiprazole and blonanserin on clinical symptoms and plasma levels of homovanillic acid (phva) and 3-methoxy-4hydroxyphenylglycol in the switching strategy of schizophrenia. |
2014-11-21 |
2023-08-12 |
Not clear |
| T Charpeaud, L Samalin, P-M Llorc. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?]. L'Encephale. vol 40. issue 1. 2014-10-28. PMID:24445245. |
[efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?]. |
2014-10-28 |
2023-08-12 |
Not clear |
| T Charpeaud, L Samalin, P-M Llorc. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?]. L'Encephale. vol 40. issue 1. 2014-10-28. PMID:24445245. |
this wide therapeutic range prompted us to investigate the existence of a possible dose-effect relationship for aripiprazole in the treatment of schizophrenia. |
2014-10-28 |
2023-08-12 |
Not clear |
| Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pa. Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric disease and treatment. vol 10. 2014-09-11. PMID:25210454. |
schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. |
2014-09-11 |
2023-08-13 |
Not clear |
| Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pa. Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric disease and treatment. vol 10. 2014-09-11. PMID:25210454. |
in this respect, the emergence of long-acting aripiprazole injection (alai), approved by the us food and drug administration for the treatment of schizophrenia in 2013, is timely. |
2014-09-11 |
2023-08-13 |
Not clear |
| Chin-Bin Yeh, Yu-Shu Huang, Ching-Shu Tang, Liang-Jen Wang, Wen-Jiun Chou, Miao-Chun Chou, Chih-Ken Che. Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. Nordic journal of psychiatry. vol 68. issue 3. 2014-09-08. PMID:23795862. |
neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. |
2014-09-08 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Ting-Gang Chang, Nan-Ying Chi. Aripiprazole associated urine retention in a male schizophrenia patient. General hospital psychiatry. vol 35. issue 6. 2014-07-03. PMID:23932666. |
aripiprazole associated urine retention in a male schizophrenia patient. |
2014-07-03 |
2023-08-12 |
Not clear |
| Priya Khanna, Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel-Kluge, Hany George El-Sayeh, Stefan Leucht, Jun Xi. Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews. issue 1. 2014-07-01. PMID:24385408. |
aripiprazole versus other atypical antipsychotics for schizophrenia. |
2014-07-01 |
2023-08-12 |
Not clear |
| S K Sha. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu University medical journal (KUMJ). vol 11. issue 42. 2014-06-23. PMID:24096218. |
a comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. |
2014-06-23 |
2023-08-12 |
Not clear |
| Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gome. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophrenia research. vol 150. issue 2-3. 2014-06-20. PMID:24035403. |
this parallel-group, 16-week study enrolled adults with schizophrenia who were receiving standard of care (soc) therapy, which included ≥3months treatment with one of four sgas: aripiprazole, olanzapine, risperidone, or quetiapine. |
2014-06-20 |
2023-08-12 |
Not clear |
| Paul N Deslandes, Arwel Thomas, Eve E Blackmore, Robert D E Sewel. Aripiprazole: 6-month outcomes in a retrospective naturalistic study. International journal of psychiatry in clinical practice. vol 12. issue 4. 2014-06-19. PMID:24937709. |
all patients with schizophrenia or schizoaffective disorder who had received aripiprazole were identified from pharmacy records, and data collected by retrospective case note review. |
2014-06-19 |
2023-08-13 |
human |
| Suresh Mallikaarjun, John M Kane, Patricia Bricmont, Robert McQuade, William Carson, Raymond Sanchez, Robert A Forbes, W Wolfgang Fleischhacke. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophrenia research. vol 150. issue 1. 2014-05-08. PMID:23890595. |
pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. |
2014-05-08 |
2023-08-12 |
human |
| Suresh Mallikaarjun, John M Kane, Patricia Bricmont, Robert McQuade, William Carson, Raymond Sanchez, Robert A Forbes, W Wolfgang Fleischhacke. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophrenia research. vol 150. issue 1. 2014-05-08. PMID:23890595. |
this 24-week, open-label, phase ib, parallel-arm, multiple-dose trial assessed the pharmacokinetics, safety and tolerability of a once-monthly injection of aripiprazole (aripiprazole once-monthly) in 41 subjects with schizophrenia. |
2014-05-08 |
2023-08-12 |
human |
| Suresh Mallikaarjun, John M Kane, Patricia Bricmont, Robert McQuade, William Carson, Raymond Sanchez, Robert A Forbes, W Wolfgang Fleischhacke. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophrenia research. vol 150. issue 1. 2014-05-08. PMID:23890595. |
in conclusion, aripiprazole once-monthly at doses of 300 and 400mg is a viable formulation for treatment of adults with schizophrenia. |
2014-05-08 |
2023-08-12 |
human |
| Deanna L Kelly, Heidi J Wehring, Amber K Earl, Kelli M Sullivan, Faith B Dickerson, Stephanie Feldman, Robert P McMahon, Robert W Buchanan, Dale Warfel, William R Keller, Bernard A Fischer, Joo-Cheol Shi. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC psychiatry. vol 13. 2014-05-08. PMID:23968123. |
treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing daamsel clinical trial (dopamine partial agonist, aripiprazole, for the management of symptomatic elevated prolactin). |
2014-05-08 |
2023-08-12 |
Not clear |
| D S Danilo. [The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 114. issue 3. 2014-05-07. PMID:24781224. |
[the use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia]. |
2014-05-07 |
2023-08-13 |
Not clear |
| David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gome. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison. Schizophrenia research and treatment. vol 2014. 2014-04-28. PMID:24772351. |
pomaglumetad methionil (ly2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. |
2014-04-28 |
2023-08-13 |
Not clear |
| David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gome. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison. Schizophrenia research and treatment. vol 2014. 2014-04-28. PMID:24772351. |
we tested the hypothesis that long-term treatment with pomaglumetad methionil would demonstrate significantly less weight gain than aripiprazole in patients with schizophrenia. |
2014-04-28 |
2023-08-13 |
Not clear |
| David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gome. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison. Schizophrenia research and treatment. vol 2014. 2014-04-28. PMID:24772351. |
in this 24-week, multicenter, randomized, double-blind, phase 3 study, 678 schizophrenia patients were randomized to either pomaglumetad methionil (n = 516) or aripiprazole (n = 162). |
2014-04-28 |
2023-08-13 |
Not clear |